Outcomes after switching from one anti|tumor necrosis factor alpha ...

Outcomes after switching from one anti-tumor necrosis factor alpha ...

RA patients who are switched to a second anti-TNF drug have high rates of continuation, although among those who must discontinue treatment, the reasons for ...

Outcomes after switching from one anti–tumor necrosis factor α ...

Overall, 73% of patients who switched to a second anti-TNF agent remained on the new therapy by the end of followup. First drug discontinuation ...

Outcomes after switching from one anti–tumor necrosis factor α ...

Overall, 73% of patients who switched to a second anti-TNF agent remained on the new therapy by the end of followup.

Effects of switching between anti-TNF therapies on HAQ response in ...

Objectives. Small studies have shown an improvement in disease activity in patients with RA who have switched between anti-TNF therapies for ...

Outcomes after switching from one anti-tumor necrosis factor α agent ...

Dive into the research topics of 'Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in ...

Switching anti-TNF-α agents: What is the evidence? - SpringerLink

Although effective and well-tolerated in a substantial proportion of patients, primary and secondary failures of anti-TNF-α strategies have been ...

Outcomes after switching from one anti–tumor necrosis factor α ...

Abstract ObjectivePatients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, ...

Efficacy in current practice of switching between anti-tumour ...

In this study, which involved 99 patients requiring a second anti-TNF-α agent, we have shown the good effect of switching. After the failure of ...

Outcomes after switching from one anti-tumor necrosis factor α agent ...

Overall, 73% of patients who switched to a second anti-TNF agent remained on the new therapy by the end of followup. First drug discontinuation ...

Switching tumor necrosis factor inhibitors in the treatment of axial ...

Switching TNF inhibitors was beneficial for a substantial proportion of patients with axSpA who failed to respond to initial or even second TNF inhibitor ...

Anti-Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation ...

Additionally, we have shown that anti-TNF-α therapy leads to a reduction in inflammation along the whole aorta, and in its MDS, as well. We ...

Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor ...

Despite improved clinical outcomes for the majority of patients, nearly 30% of patients with rheumatoid arthritis (RA) who initiate tumor ...

Outcomes after switching from one anti–tumor necros... | PDF or Rental

Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either ...

Outcomes of tumor necrosis factor inhibitor cycling versus switching ...

In the analysis of overall treatment patterns during the 12-month post-switch period ( Figure 2(a) ), new MOA switchers were more likely than TNFi cyclers to ...

Clinical application and evaluation of anti-TNF-alpha agents for the ...

RA patients who experience treatment failure with one anti-TNF-α agent, due to either inefficacy or toxicity, are frequently switched to a ...

Strategies after the failure of the first anti-tumor necrosis factor α ...

According to these results, patients on anti-TNF-α therapy not tolerating MTX could be switched to a combination with leflunomide [22]. 4.2.

20 years of experience with tumour necrosis factor inhibitors

The effectiveness of a TNFi therapy in reducing RA-related disability has also been confirmed in patients with highly active and long-standing ...

Association Between Tumor Necrosis Factor Inhibitor Exposure and ...

Exposure to TNF inhibitors occurred in 64 patients (60%) and 42 control participants (40%) and was associated with an increased risk of any ...

Discontinuation and Switchback After Non-Medical Switching from ...

To examine the prevalence rates of biosimilar discontinuation and switchback to the originator tumor necrosis factor alpha (TNF) inhibitors ...

Cost-utility analysis of treatment options after initial tumor necrosis ...

RESULTS: Switching to abatacept after the first TNFi showed an incremental cost of just more than $11,300 over 10 years and achieved a QALY ...